TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Soft Tissue SarcomaMelanoma
Interventions
DRUG

TQB2916 injection + doxorubicin hydrochloride for injection

"TQB2916 is a humanized immune gamma globulins 2 (IgG2) monoclonal antibody targeting CD40.~The mechanism of action of doxorubicin is mainly to destroy the DNA structure of tumor cells, thereby killing malignant tumors. It interferes with the DNA synthesis process of cancer cells by targeting DNA and inhibiting enzymes in DNA replication and repair. In addition, doxorubicin can also trigger cross-link breaks in DNA, leading to apoptosis of cancer cells."

DRUG

TQB2916 injection+penpulimab injection

TQB2916 is a humanized IgG2 monoclonal antibody targeting CD40. Penpulimab injection is a programmed cell death protein 1 (PD-1) immune checkpoint inhibitor.

Trial Locations (11)

100021

Cancer Hospital Chinese Academy of Medical Science, Beijing

100142

Beijing Cancer Hospital, Beijing

130012

Jilin Cancer Hospital, Changchun

200032

Fudan University Shanghai Cancer Center, Shanghai

250117

Cancer Hospital Affiliated to Shandong First Medical University, Jinan

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

310022

Zhe Jiang Cancer Hospital, Hangzhou

410000

Hunan Cancer Hospital, Changsha

450000

Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou

830000

Xinjiang Medical University Affiliated Cancer Hospital, Ürümqi

030000

Shanxi Cancer Hospital, Taiyuan

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY